Clinical trial • Phase III • Infectious Disease

Clindamycin for Planned limb amputation

Phase III trial of Clindamycin for Planned limb amputation. 24 participants.

Overview

Trial Therapeutic Area
Infectious Disease
Trial Disease
Planned limb amputation
Trial Stage
Phase III
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
13-09-2024
First CTIS Authorization Date
14-10-2024

Trial design

Phase III trial across 1 site in Austria.

Target Sample Size
24

Eligibility

Recruits 24 No vulnerable populations selected..

Vulnerable Population
No vulnerable populations selected.

Recruitment

Planned Sample Size
24
Recruitment Window Months
36

Geography

Total Number Of Sites
1
Total Number Of Participants
24

Austria

Earliest CTIS Part Ii Submission Date
25-09-2024
Latest Decision Or Authorization Date
06-11-2025
Processing Time Days
407
Number Of Sites
1
Number Of Participants
24

Sites

Site Name
Medical University Of Vienna
Department Name
Department of Clinical Pharmacology
Principal Investigator Name
Markus Zeitlinger
Principal Investigator Email
markus.zeitlinger@meduniwien.ac.at
Contact Person Name
Markus Zeitlinger
Number Of Participants
24

Sponsor

Primary sponsor

Full Name
Medical University Of Vienna
Organisation Type
Educational Institution
Country Of Registered Address
Austria

Investigational products

Investigational Product Name
Clindamycin
Active Substance
Clindamycin
Modality
Small molecule
Investigational Product Name
Cefalexin
Active Substance
Cefalexin
Modality
Small molecule

Related trials

Other published trials that may interest you.